Please enable Javascript
Myelofibrosis
The latest news, research, and perspectives in myelofibrosis (MF). A primary subtype of myeloproliferative neoplasms (MPNs), this rare blood cancer scars the bone marrow so that it cannot properly produce blood cells.
Advertisement
Study Compares Blast Reduction Strategies in Accelerated, Blast Phase MPN
Melissa Badamo
Myelofibrosis
|
April 4, 2024
The primary endpoint was overall best response after blast-reduction therapy.
Read More
Bone Marrow Fibrosis Improvements Not Linked With Myelofibrosis Treatment Benefits
Blood Cancers Today Staff Writers
Myelofibrosis
|
April 1, 2024
Momelotinib and ruxolitinib improved bone marrow fibrosis, but changes were not associated with improved outcomes in MF.
Read More
What Is the Impact of GVHD on Myelofibrosis Relapse After HSCT?
Nicolaus Kröger, MD
Myelofibrosis
|
March 4, 2024
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
View More
Prithviraj Bose, MD, on the Importance of Rare Disease Day
Prithviraj Bose, MD
Myelofibrosis
|
February 29, 2024
Myelofibrosis, a rare blood cancer, affects four to six per 100,000 individuals in the United States.
View More
International Working Group Publishes Updated Guidelines for HSCT in Myelofibrosis
Patrick Daly
Myelofibrosis
|
March 22, 2024
An international working group collaborating with the EBMT and ELN updated the 2015 guidelines for HSCT in myelofibrosis.
Read More
Combination Therapy Demonstrates ‘Potential Disease-Modifying Activity’ in Myelofibrosis
Melissa Badamo
Myelofibrosis
|
February 28, 2024
Ruxolitinib plus pelabresib was well tolerated and improved spleen and symptom burden in patients with myelofibrosis.
Read More
Advertisement
Adding Parsaclisib to Ruxolitinib Improves Myelofibrosis Symptoms, Spleen Volume
Keightley Amen
Myelofibrosis
|
February 26, 2024
Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis.
Read More
Claire Harrison, MD, on the FREEDOM2 Study in Myelofibrosis
Claire Harrison, MD, FRCP, FRCPath
Myelofibrosis
|
February 29, 2024
FREEDOM2 is a phase III study comparing fedratinib with best available therapy as a second-line treatment for myelofibrosis.
View More
Study Investigates Effects of Splicing Mutations in Secondary Myelofibrosis
Leah Sherwood
Myelofibrosis
|
March 4, 2024
“Among the high-risk splicing mutations, SRSF2 has the worst prognostic role,” Dr. Braish and colleagues wrote.
Read More
Risk Factors for Disease Progression in Patients with PV
Michael Grunwald, MD
Myeloproliferative Neoplasms
|
December 14, 2023
The REVEAL study identified five risk factors, including leukocytosis, duration of time with PV, and more.
View More
ALK2 Inhibitor Improves Anemia Due to Myelofibrosis
Patrick Daly
Myelofibrosis
|
March 1, 2024
The treatment led to reduced hepcidin levels when used alone or in combination with ruxolitinib.
Read More
Dr. Venugopal Highlights Myelofibrosis Research at ASH 2023
Sangeetha Venugopal, MD
Myelofibrosis
|
March 4, 2024
Venugopal highlights myelofibrosis research at ASH 2023.
View More
Haifa Kathrin Al-Ali, MD, Covers Outcomes of Combined BET, JAK Inhibition in Myelofibrosis
Haifa Kathrin Al-Ali, MD
Myelofibrosis
|
March 4, 2024
Dr. Al-Ali covers data on combined BET and JAK inhibition for patients with myelofibrosis presented at the 2023 ASH Meeting.
View More
What Is the Role of Splicing Mutations in Patients with Myelofibrosis?
Melissa Badamo
Myelofibrosis
|
December 11, 2023
SRSF2 and SF3B1 were the most common splicing mutations, followed by U2AF1 and ZRSR2.
Read More
Nico Gagelmann, MD, on Driver Mutation Clearance After Stem Cell Transplantation
Nico Gagelmann, MD
Myelofibrosis
|
March 4, 2024
CALR and MPL mutations, which are associated with better outcomes, showed earlier mutation clearance than JAK2.
View More
Mouse Study Aids Understanding of Myelofibrosis Drivers
Emily Hayes
Myelofibrosis
|
March 4, 2024
Mass spectrometry–based proteomics were used to learn more about how MKs drive bone marrow fibrosis.
Read More
Myelofibrosis Takes Toll on Quality of Life
Emily Hayes
Myelofibrosis
|
March 4, 2024
Prevalence of symptoms was assessed with the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score.
Read More
Pacritinib Boosts Platelet Counts in Cytopenic Myelofibrosis
Emily Hayes
Myelofibrosis
|
March 4, 2024
The retrospective study evaluated if pacritinib increased PLT counts in the phase III PERSIST-2 and phase II PAC203 studies.
Read More
Ropeginterferon Alfa-2b Is an Effective Treatment for Prefibrotic Primary Myelofibrosis
Blood Cancers Today Staff Writers
Myelofibrosis
|
March 4, 2024
Responses in hemoglobin, white blood cell, and platelet were 75%, 82%, and 74%, respectively, at 24 weeks.
Read More
ATG Is an Effective GVHD Prophylaxis in Patients with Myelofibrosis
Blood Cancers Today Staff Writers
Myelofibrosis
|
March 4, 2024
Multivariable modeling showed a notable reduction in the risk of GVHD or relapse in the ATG group.
Read More
Load More
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACP
Editor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MD
Associate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MD
Executive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MD
Associate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MD
Associate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MD
Associate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPH
Associate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer